Latvian Biomedical Research and Study centre

MGI Kicks Off ICG-17 in Riga with Launch of DNBSEQ-T7** HotMPS High-Throughput Sequencing Kit* and Spatial Transcriptomics Grant Program

Retrieved on: 
Wednesday, September 7, 2022
Software, Enzyme, COVID-19, Technology, BGI Group, Research, Agriculture, Precision medicine, Science, MUST, Medicine, Twitter, Risk, ICG, RNA transfection, MGI, Automation, ALL, RNA-Seq, Gene expression, DNB, BGI, DNA nanoball sequencing, Woman, Information Systems International Conference, General manager, CID, List of Nobel laureates, LinkedIn, Data analysis, Patent, Latvian Biomedical Research and Study centre, University, WES, Biomedical Research, YouTube, WGS, OMICS, Nucleotide, Chemistry, University of Debrecen, Conference, Stereophonic sound, Knowledge, G400, Fine chemical, Medical imaging, Hydraulic machinery, Genomics

At ICG-17, MGI introduces its new commercial sequencing chemistry HotMPS* and together with BGI STOmics, a spatial transcriptomics grant program.

Key Points: 
  • At ICG-17, MGI introduces its new commercial sequencing chemistry HotMPS* and together with BGI STOmics, a spatial transcriptomics grant program.
  • At the ICG-17 in Riga, BGI STOmics announces a spatial transcriptomics grant program, which will provide 12 Stereo-seq (Spatial Enhanced Resolution Omics-Sequencing) chips (1cm*1cm), sequencing and data analysis to selected projects by researchers across the globe, excluding mainland China.
  • MGI will provide MGI sequencing products for this Grant.
  • **This sequencer is only available in selected countries, and its software has been specially configured to be used in conjunction with MGI's HotMPS sequencing reagents exclusively.

Amolyt Pharma to Host Hybrid Key Opinion Leader Event on its Potential Hypoparathyroidism Treatment, AZP-3601, on Monday, September 12th at 1:30pm CT/2:30pm ET in Austin, Texas

Retrieved on: 
Wednesday, September 7, 2022
Acromegaly, Doctor of Science, Osteoporosis, Study, Genetics, Doctor of Philosophy, Semmelweis University, Disease, Medical school, Internal medicine, Endocrinology, LinkedIn, Department, Latvian Biomedical Research and Study centre, Department of Medicine – University of Pamplona, Hypoparathyroidism, Student, Thyroid, MD, GLOBE, Pharmacology, Twitter, Osteology, Association, PTH, Hungarian Academy of Sciences, Patient, Fine chemical, Pharmaceutical industry, Medicine, Research

The event will also be webcast for those who are unable to attend in person.

Key Points: 
  • The event will also be webcast for those who are unable to attend in person.
  • Professor Istvn Takcs obtained his MD in 1989 from Semmelweis University, Faculty of Medicine, in Budapest, Hungary.
  • He was board certified in internal medicine in 1994, in endocrinology in 1997 and in clinical pharmacology in 2001.
  • To learn more, visit https://amolytpharma.com/ or follow us on Twitter at @AmolytPharma or on LinkedIn .

HypoPARAthyroidism Association Launches the First-of-its-Kind Patient-Powered Data Platform to Advance Patient Care

Retrieved on: 
Tuesday, June 21, 2022
Broad Institute, Chronic kidney disease, Lists of diseases, Heart, Latvian Biomedical Research and Study centre, Association, Education, FDA, Customer data platform, Technology, Wheeze, Biology, MIT, Cataract, Brain, PTH, Calcium, Parathyroid hormone, Hyperphosphatemia, Disorder, Hypercalciuria, Seizure, Disease, Urine, Natural history, Nervous system, Health, Harvard University, Quality of life, Caregiver, Hypocalcemia, Mineral, Arrhythmia, American Association of Clinical Endocrinologists, Partnership, Data collection, Cramp, Patient, Calcium citrate, Time-invariant system, Diagnosis, Serum, Calcium carbonate, Blood, GLOBE, Organization, Pharmaceutical industry, Phosphorus, Hypoparathyroidism, Research

LEMOORE, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- HypoPARAthyroidism Association, Inc., an organization dedicated to improving the lives of people impacted by hypoparathyroidism (HypoPARA) through education, support, research, and advocacy, today announced the launch of the first-of-its-kind Patient-Powered Data Platform. The platform will aggregate data voluntarily entered by patients about their disease, medical history and quality of life, with the long-term goal of building a patient-driven data repository that can help healthcare providers, researchers and clinicians make informed decisions about the treatments for people living with HypoPARA. This launch is a critical first step to broadening the HypoPARA research journey and an important resource for patients and their caregivers to advance care for the HypoPARA communities.

Key Points: 
  • This launch is a critical first step to broadening the HypoPARA research journey and an important resource for patients and their caregivers to advance care for the HypoPARA communities.
  • The Data Platform is designed to inform researchers understanding of how the symptoms of HypoPARA, or response to therapy, change over time.
  • The Patient-Powered Data Platform will also make it easier to identify endocrinologists and other specialists who may have expertise in treating HypoPARA.
  • HypoPARAthyroidism Association, Inc., is dedicated to improving the lives of people impacted by hypoparathyroidism (HypoPARA) through education, support, research, and advocacy.